Vita 34 : Publishes Preliminary Figures for Fiscal Year 2014

Vita 34 AG Publishes Preliminary Figures for Fiscal Year 2014

- Total operating revenue higher than prior year

- High level of profitability: EBITDA margin continues to be strong at 20.1 percent

- Earnings per share increased by 28.6 percent

Leipzig, 05 March 2015 - Vita 34 AG (WKN A0BL84), a pioneer in the storage of stem cells from umbilical cord blood and tissue, and a specialist in cryo-preservation improved the group key figures in fiscal year 2014 as compared with the prior year, and fulfilled the prognosis for fiscal year 2014 that had been updated in Q3.

According to preliminary figures, the total operating revenue increased to EUR 15.2 million in fiscal year 2014 and was 2.7 percent higher than the prior year's value of EUR 14.8 million. Sales revenues increased to EUR 13.8 million following EUR 13.6 million in fiscal year 2013. The growth in revenues can be mainly attributed to the increased number of newly stored stem cell deposits of umbilical cord blood and tissue. In the reporting period they increased by some 2.9 percent as compared with the prior year to 7,378 stem cell deposits. EBITDA improved from EUR 2.7 million in fiscal year 2013 to EUR 2.8 million in the reporting period. This is equivalent to a high EBITDA margin of 20.1 percent (2013: 19.6 percent). The operating profit (EBIT) increased as well and amounted to EUR 1.7 million in fiscal year 2014, following EUR 1.5 million the prior year, corresponding to an EBIT margin of 12.3 percent (2013: 10.8 percent). The period result improved to EUR 1.0 million following EUR 0.8 million in the 2013 reference period. The earnings per share, based on the period result attributable to holders of common stock of the parent company, increased by 28.6 percent to EUR 0.36 (2013: EUR 0.28).

"We set decisive measures in fiscal year 2014 and consider ourselves to be on the right path. The EBITDA margin of 20.1 percent underscores the profitability of our business activities," commented Dr. André Gerth, CEO of Vita 34 AG. "The key to the positive business development lies in the consistent implementation of our growth strategy. We have achieved significant milestones with the acquisition of the business of Austrian market leader Vivocell as of January 2, 2015 as an asset deal, the extension of cooperations with partners in other countries, as well as with the product launch of VitaPlusNabelschnur [VitaPlusCord] in Europe in fiscal year 2014."

In the first months of 2015, Vita 34 has followed the prior year's lead and entered into a cooperation agreement with the Baltic stem cell bank AS "Imunolita." With the associated market entry in the Baltic states, Vita 34 is now active in 20 countries apart from Germany. In the current fiscal year Vita 34 expects a total operating revenue and an EBITDA at the level of 2014.

The complete Annual Report 2014 will be available for download as of March 26, 2015 on the company website at www.vita34group.com in the "Investor Relations" section.

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. More than 123,000 families are already taking advantage of this offering and have provided with a stem cell deposit at Vita 34.